Skip to main content
Erschienen in:

03.08.2020 | Letter to the Editor

Moderate hypofractionation for early laryngeal cancer improves local control with increased risk of mucositis: clarification

verfasst von: Rony Benson, Prashanth Giridhar, Supriya Mallick

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Excerpt

We would like to provide a point-wise clarification to the concerns raised in the letter to editor manuscript number: EAOR-D-20-00971. A query was raised in the letter to editor to clarify if the meta-analysis included only early glottic cancers or had included all laryngeal cancers. The present meta-analysis tested hypofractionation versus conventional fractionation in early laryngeal cancer including glottic and supraglottic cancer. The idea of hypofractionation was initially tested in only early glottic cancer with subsequent studies including supraglottic larynx as well. Due to lack of data, subset analysis on each sub-site as well as volume of radiotherapy was not done. We acknowledge the inadvertent error in the abstract. Another clarification sought by the author was whether Embase search was conducted. We would like to state that a comprehensive systematic search of Embase was done and no additional studies were found. We acknowledge that writing ‘Embase = 0 articles’ was missed in the PRISMA chart [1]. The third query raised was regarding the analysis of dichotomous variables. Dichotomous variables can be described in terms of odds ratio or risk ratio. Often interpreting risk ratio is easier for clinicians; therefore, is more commonly used [2]. We would like to state that both odds ratio and risk ratio were calculated in the present meta-analysis. The risk ratio using random effects model for acute mucositis was 1.17 (95% CI 1.043–1.312); p value 0.007; I2 = 0%. The interpretation of this result remains that hypofractionation is associated with increased mucositis compared with conventional fractionation in early laryngeal cancers as described in our article. Another query raised by our fellow researcher is whether the number of patients in the intervention (hypofractionation) arm from the Yamazaki article was 91 or 92. The original article by Yamazaki et al. actually creates this confusion, where in it is stated in the abstract that there were 91 patients while in the tables in the article proper, it is stated as 92 [3]. So, we had to run the statistical analysis considering both 91 or 92 patients in the intervention arm and 88 or 89 patients in the control arm. The results in any combination showed that the hypofractionation arm is associated with a higher mucositis. …
Literatur
2.
Zurück zum Zitat Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (2019) Cochrane handbook for systematic reviews of interventions, 2nd edn, pp 246–8 Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (2019) Cochrane handbook for systematic reviews of interventions, 2nd edn, pp 246–8
3.
Zurück zum Zitat Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M (2006) Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 64(1):77–82CrossRef Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M (2006) Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 64(1):77–82CrossRef
Metadaten
Titel
Moderate hypofractionation for early laryngeal cancer improves local control with increased risk of mucositis: clarification
verfasst von
Rony Benson
Prashanth Giridhar
Supriya Mallick
Publikationsdatum
03.08.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology / Ausgabe 10/2020
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-020-06257-4

Neu im Fachgebiet HNO

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Kopf-Hals-Tumore: Lebensqualität von Langzeitüberlebenden

Eine aktuelle Studie des Universitätsklinikums Erlangen verdeutlicht, dass Langzeitüberlebende von Kopf-Hals-Tumoren eine geringe Symptomlast aufweisen. Die am häufigsten auftretenden Beschwerden – Müdigkeit, Angstzustände, Schläfrigkeit und Schmerzen – sollten von den behandelnden Ärztinnen und Ärzten gezielt adressiert werden.

Schlafapnoe – es lag an einer verbogenen Nasenscheidewand

Tritt eine obstruktive Schlafapnoe vor allem in einer bestimmten Seitenlage auf, kann dies auch an einem verbogenen Nasenseptum liegen. Eine Septumplastik lindert die Beschwerden mitunter deutlich.

Das alles ändert sich für Arztpraxen in 2025

  • 31.12.2024
  • EBM
  • Nachrichten

Ab Januar greifen jede Menge Neuerungen – ob im EBM, Arbeits- und Steuerrecht oder bei der digitalen Vernetzung. Darunter einige Verbesserungen, aber teils auch Mehraufwand. „Same procedure as every year?“ – Ein Überblick.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.